Formulation of sustained release aqueous Zn-hirudin suspensions

European Journal of Pharmaceutical Sciences

Volumn 11, Issue 1, 2000, Pages 33-41

  Gietz, Ursula ^a   Arvinte, Tudor ^b   Häner, Markus ^c   Aebi, Ueli ^c   Merkle, Hans P ^a  

^a Drug Formulation Delivery Swiss F ^*  (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Basic zinc salts; Protein precipitation; Recombinant hirudin; Sustained release formulation; Zinc chloride; Zinc sulfate

Indexed keywords

RECOMBINANT HIRUDIN; ZINC CHLORIDE; ZINC SULFATE;

ANTICOAGULATION; AQUEOUS SOLUTION; ARTICLE; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; ELECTRON MICROSCOPY; MICROSCOPY; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; SUSPENSION; SUSTAINED RELEASE FORMULATION; TECHNIQUE;

ANTITHROMBINS; CHLORIDES; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG STORAGE; HIRUDINS; HYDROGEN-ION CONCENTRATION; PRECIPITATION; SOLUBILITY; ZINC COMPOUNDS; ZINC SULFATE;

EID: 0034083853     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(00)00072-5     Document Type: Article

References (25)

1. Arakawa T., Timasheff S.N. Mechanism of protein salting in and salting out by divalent cation salts: balance between hydration and salt binding. Biochemistry. 23:1984;5912-5923.
2. Arvinte, T., 1994. Pharmaceutical compositions containing hirudin. European Patent 0624375A2.
3. Chang J.-Y., Grossenbacher H., Meyhack B., Märki W. Production of disulfide-linked hirudin dimer by in vitro folding. FEBS Lett. 336:1993;53-56.
4. Crause, P., Habermann, P., Kramer, M., Obermeier, R., Sauber, K., Tripier, D., 1995. Hirudin-Derivate mit verzögerter Wirkung. European Patent 0345616B1.
5. Fareed J., Walenga J.M., Hoppensteadt D., Iqbal O., Rübsamen K. Comparative pharmacodynamics of recombinant hirudin and its PEG-coupled derivatives in primates. Abstr. Thromb. Haemost. 65:1991;1286.
6. Feitknecht W. Untersuchungen über die Umsetzung fester Stoffe in Flüssigkeiten. 1. Mitteilung: Ueber einige basische Zinksalze. Helv. Chim. Acta. 12:1929;22-43.
7. Forrer K., Girardot P., Dettwiler M., Märki W., Grossenbacher H., Gassmann E. Different modes of capillary electrophoresis for the analysis of recombinant hirudin. Proc. 9th Int. Symp. on Capillary Electrophoresis, Budapest, Hungary :1994.
8. Fries J., Getrost H. Organische Reagenzien für die Spurenanalyse. 1975;402-404 Merck, Darmstadt.
9. Gietz U., Arvinte T., Mader E., Oroszlan P., Merkle H.P. Sustained release of injectable zinc-recombinant hirudin suspensions: development and validation of in vitro release model. Eur. J. Pharm. Biopharm. 45:1998;259-264.
10. Glatz C.E. Modeling of aggregation-precipitation phenomena. Ahern T.J., Manning M.C. Stability of Protein Pharmaceuticals. Chemical and Physical Pathways of Protein Degradation. 1992;135 Plenum Press, New York. Section A.
11. Hallas-Möller K., Petersen K., Schlichtkrull J. Crystalline and amorphous insulin-zinc compounds with prolonged action. Science. 116:1952;394-398.
12. Hegedüs I. A nitration elnyelesi szinkepenek valtozasarol. Acta Chim. Mineralogr. Phys. (Szeged). 7:1939;7-25.
13. Homan J.D.H., Overbeek G.A., Neutelings J.P.J., Booij C.J., Van der Vies J. Corticotrophin zinc phosphate and hydroxide. Lancet. 13:1954;541-542.
14. Markwardt F. Untersuchungen über Hirudin. Naturwissenschaften. 42:1955;537-538.
15. Markwardt F. Die Isolierung und chemische Charakterisierung des Hirudins. Hoppe Seyler's Ztschr. Physiol. Chem. 308:1957;147-157.
16. Markwardt F., Richter M., Walsmann P., Riesener G., Paintz M. Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behavior. Biomed. Biochim. Acta. 49:1990;1103-1108.
17. Masuoka J., Hegenauer J., Van Dyke B.R., Saltman P. Intrinsic stoichiometric equilibrium constants for the binding of zinc(II) and copper(II) to the high affinity site of serum albumin. J. Biol. Chem. 268:1993;21533-21537.
18. Rydel T.J., Ravichandran K.G., Tulinsky A., Bode W., Huber R., Roitsch C., Fenton J.W. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science. 247:1990;277-280.
19. Schlichtkrull, J., 1958. Insulin crystals. DSc thesis, Munksgaard Publishers, Copenhagen, p. 61.
20. Spiro T.G., Saltman P. Polynuclear complexes of iron and their biological implications. Hemmerich P., Jörgensen C.K., Neillands J.B., Nyholm R.S., Reinen D., Williams R.J.P. Structure and Bonding. Vol. 6:1969;116 Springer, New York.
21. Timasheff S.N., Arakawa T. Stabilization of protein structure by solvents. Creighton T.E. Protein Structure, A Practical Approach. 1990;331 IRL Press, Oxford.
22. Wrigley N.G. The lattice spacing of crystalline catalase as an internal standard of length in electron microscopy. J. Ultrastruct. Res. 24:1968;454-464.
23. Yoe J.H., Rush R.M. A new colorimetric reagent for zinc. Anal. Chim. Acta. 6:1952;526-527.
24. Zawilska K., Zozulinska M., Turowiecka Z., Blahut M., Drobnik L., Vinazzer H. The effect of a long-acting recombinant hirudin (PEG-hirudin) on experimental disseminated intravascular coagulation (DIC) in rabbits. Thromb. Res. 69:1993;315-320.
25. Zoldhelyi P., Webster M.W.I., Fuster V., Grill D.E., Gaspar D., Edwards S.J., Cabot C.F., Chesebro J.H. Recombinant hirudin in patients with chronic, stable coronary artery disease. Circulation. 88:1993;2015-2022.